Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus: From Genes to Organ Damage

  • Protocol
  • First Online:
Systems Biology in Drug Discovery and Development

Part of the book series: Methods in Molecular Biology ((MIMB,volume 662))

Abstract

Systemic lupus erythematosus (SLE) is a disease characterized by inappropriate response to self-antigens. Genetic, environmental and hormonal factors are believed to contribute to the development of the disease. We think of SLE pathogenesis as occurring in three phases of variable duration. A series of regulatory failures during the ontogeny of the immune system lead to the emergence of auto-reactive clones and the production of auto-antibodies (phase I). As the immune response to self-antigens broadens, the auto-antibody repertoire is enriched (phase II) and clinical manifestations eventually ensue (phase III). The final result is tissue damage that if not treated will lead to the functional failure of such important organs as the kidney and brain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Krishnan S, Chowdhury B, Juang Y-T, Tsokos GC (2007) Overview of the pathogenesis of systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 55–63

    Chapter  Google Scholar 

  2. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799

    Article  CAS  PubMed  Google Scholar 

  3. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270

    Article  CAS  PubMed  Google Scholar 

  4. Siegel M, Lee SL (1973) The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 3:1–54

    Article  CAS  PubMed  Google Scholar 

  5. Nossent JC (1992) Systemic lupus erythematosus on the Caribbean island of Curacao: an epidemiological investigation. Ann Rheum Dis 51:1197–1201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Vilar MJ, Sato EI (2002) Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus 11:528–532

    Article  PubMed  Google Scholar 

  7. McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270

    Article  CAS  PubMed  Google Scholar 

  8. Lahita RG (1999) The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 11:352–356

    Article  CAS  PubMed  Google Scholar 

  9. Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA (2002) Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus 11:722–729

    Article  CAS  PubMed  Google Scholar 

  10. Soto ME, Vallejo M, Guillen F, Simon JA, Arena E, Reyes PA (2004) Gender impact in systemic lupus erythematosus. Clin Exp Rheumatol 22:713–721

    CAS  PubMed  Google Scholar 

  11. Tucker LB, Menon S, Isenberg DA (1995) Systemic lupus in children: daughter of the Hydra? Lupus 4:83–85

    Article  CAS  PubMed  Google Scholar 

  12. Mak SK, Lam EK, Wong AK (1998) Clinical profile of patients with late-onset SLE: not a benign subgroup. Lupus 7:23–28

    Article  CAS  PubMed  Google Scholar 

  13. Baker SB, Rovira JR, Campion EW, Mills JA (1979) Late onset systemic lupus erythematosus. Am J Med 66:727–732

    Article  CAS  PubMed  Google Scholar 

  14. Hochberg MC (1985) The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977. Arthritis Rheum 28:80–86

    Article  CAS  PubMed  Google Scholar 

  15. Ward MM, Studenski S (1990) Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 150:849–853

    Article  CAS  PubMed  Google Scholar 

  16. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM (1992) A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311–318

    Article  CAS  PubMed  Google Scholar 

  17. Werth VP (2005) Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 4:296–302

    Article  PubMed  Google Scholar 

  18. James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, Harley JB (2001) Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 44:1122–1126

    Article  CAS  PubMed  Google Scholar 

  19. Hochberg M (1997) Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  20. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1, 000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124

    Article  CAS  Google Scholar 

  21. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarcon-Segovia D (2004) The GLADEL multinational Latin American prospective inception cohort of 1, 214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore) 83:1–17

    Article  Google Scholar 

  22. Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123:42–53

    Article  CAS  PubMed  Google Scholar 

  23. Boumpas DT, Austin HA III, Fessler BJ, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940–950

    Article  CAS  PubMed  Google Scholar 

  24. Al-Maini M, Urowitz M (2007) Systemic steroids. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 487–498

    Chapter  Google Scholar 

  25. Papadimitraki E, Boumpas DD (2007) Cytotoxic drug treatment. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus: a companion to Rheumatology, 1st edn. Mosby Inc, Philadelphia, pp 498–510

    Google Scholar 

  26. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228

    Article  CAS  PubMed  Google Scholar 

  27. Houssiau FA, Ginzler EM (2008) Current treatment of lupus nephritis. Lupus 17:426–430

    Article  CAS  PubMed  Google Scholar 

  28. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537

    Article  CAS  PubMed  Google Scholar 

  29. Rahman A, Hiepe F (2002) Anti-DNA antibodies – overview of assays and clinical correlations. Lupus 11:770–773

    Article  CAS  PubMed  Google Scholar 

  30. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533

    Article  CAS  PubMed  Google Scholar 

  31. Illei GG, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 6:382–390

    Article  PubMed  Google Scholar 

  32. Jerdan MS, Hood AF, Moore GW, Callen JP (1990) Histopathologic comparison of the subsets of lupus erythematosus. Arch Dermatol 126:52–55

    Article  CAS  PubMed  Google Scholar 

  33. Tsao BP (2004) Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 16:513–521

    Article  CAS  PubMed  Google Scholar 

  34. Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR, Baechler EC, Rohlf KE, Shark KB, Espe KJ, Green LE, Nair RP, Stuart PE, Elder JT, King RA, Moser KL, Gaffney PM, Bugawan TL, Erlich HA, Rich SS, Gregersen PK, Behrens TW (2002) Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. Am J Hum Genet 71:543–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R, Cervera R, de Ramon Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Passiu G, Papasteriades C, Piette JC, Smolen J, Porciello G, Marcolongo R (2002) HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) 81:169–178

    Article  CAS  Google Scholar 

  36. Rajagopalan S, Zordan T, Tsokos GC, Datta SK (1990) Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA 87:7020–7024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Shivakumar S, Tsokos GC, Datta SK (1989) T cell receptor alpha/beta expressing double-negative (CD4−/CD8−) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 143:103–112

    CAS  PubMed  Google Scholar 

  38. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC (1998) Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest 101:1448–1457

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 172:7821–7831

    Article  CAS  PubMed  Google Scholar 

  40. Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC (2001) Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 44:1114–1121

    Article  CAS  PubMed  Google Scholar 

  41. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT (2003) Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 24:259–263

    Article  CAS  PubMed  Google Scholar 

  42. Krishnan S, Warke VG, Nambiar MP, Tsokos GC, Farber DL (2003) The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol 170:4189–4195

    Article  CAS  PubMed  Google Scholar 

  43. Juang YT, Tenbrock K, Nambiar MP, Gourley MF, Tsokos GC (2002) Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol 169:6048–6055

    Article  CAS  PubMed  Google Scholar 

  44. Chowdhury B, Tsokos CG, Krishnan S, Robertson J, Fisher CU, Warke RG, Warke VG, Nambiar MP, Tsokos GC (2005) Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3′-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem 280:18959–18966

    Article  CAS  PubMed  Google Scholar 

  45. Tsuzaka K, Setoyama Y, Yoshimoto K, Shiraishi K, Suzuki K, Abe T, Takeuchi T (2005) A splice variant of the TCR zeta mRNA lacking exon 7 leads to the down-regulation of TCR zeta, the TCR/CD3 complex, and IL-2 production in systemic lupus erythematosus T cells. J Immunol 174:3518–3525

    Article  CAS  PubMed  Google Scholar 

  46. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA (1983) Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 130:2651–2655

    CAS  PubMed  Google Scholar 

  47. Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4 + CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178:2579–2588

    Article  CAS  PubMed  Google Scholar 

  48. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Nochy D, Debre P, Piette JC, Gorochov G (2005) Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 175:8392–8400

    Article  CAS  PubMed  Google Scholar 

  49. Herndon TM, Juang YT, Solomou EE, Rothwell SW, Gourley MF, Tsokos GC (2002) Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin Immunol 103:145–153

    Article  CAS  PubMed  Google Scholar 

  50. Kyttaris VC, Juang YT, Tenbrock K, Weinstein A, Tsokos GC (2004) Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 173:3557–3563

    Article  CAS  PubMed  Google Scholar 

  51. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC (2005) Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 115:3193–3204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Solomou EE, Juang YT, Gourley MF, Kammer GM, Tsokos GC (2001) Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol 166:4216–4222

    Article  CAS  PubMed  Google Scholar 

  53. Tenbrock K, Juang YT, Gourley MF, Nambiar MP, Tsokos GC (2002) Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J Immunol 169:4147–4152

    Article  CAS  PubMed  Google Scholar 

  54. Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC (2007) Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in t cells from patients with systemic lupus erythematosus. J Immunol 178:1960–1966

    Article  CAS  PubMed  Google Scholar 

  55. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97:2063–2073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Xu L, Zhang L, Yi Y, Kang HK, Datta SK (2004) Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411–415

    Article  CAS  PubMed  Google Scholar 

  57. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, Tsokos GC (2007) Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 178:1938–1947

    Article  CAS  PubMed  Google Scholar 

  58. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC (2008) Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181:8761–8766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK (2002) Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. J Immunol 168:5070–5078

    Article  CAS  PubMed  Google Scholar 

  60. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225–252

    Article  CAS  PubMed  Google Scholar 

  61. Hudson LL, Rocca K, Song YW, Pandey JP (2002) CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region. Hum Genet 111:452–455

    Article  CAS  PubMed  Google Scholar 

  62. Wong CK, Lit LCW, Tam LS, Li EK, Lam CWK (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44:989–994

    Article  CAS  Google Scholar 

  63. Cloutier JF, Veillette A (1996) Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J 15:4909–4918

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Cloutier JF, Veillette A (1999) Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 189:111–121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW (2004) Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 75:504–507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105:4390–4398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201:703–711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of Systemic Lupus Erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358:900–909

    Article  CAS  PubMed  Google Scholar 

  69. Tretter T, Ross AE, Dordai DI, Desiderio S (2003) Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk. J Exp Med 198:1863–1873

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98:2549–2557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC (2001) Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol 101:130–135

    Article  CAS  PubMed  Google Scholar 

  72. Mackay M, Stanevsky A, Wang T, Aranow C, Li M, Koenig S, Ravetch JV, Diamond B (2006) Selective dysregulation of the Fc{gamma}IIB receptor on memory B cells in SLE. J Exp Med 203:2157–2164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, Kyttaris VC, Tsokos GC (2005) Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 115:996–1005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188:2313–2320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431–456

    Article  CAS  PubMed  Google Scholar 

  76. Ghebrehiwet B, Peerschke EI (2004) Role of C1q and C1q receptors in the pathogenesis of systemic lupus erythematosus. Curr Dir Autoimmun 7:87–97

    Article  CAS  PubMed  Google Scholar 

  77. Slingsby JH, Norsworthy P, Pearce G, Vaishnaw AK, Issler H, Morley BJ, Walport MJ (1996) Homozygous hereditary C1q deficiency and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families. Arthritis Rheum 39:663–670

    Article  CAS  PubMed  Google Scholar 

  78. Senaldi G, Davies ET, Peakman M, Vergani D, Lu J, Reid KB (1995) Frequency of mannose-binding protein deficiency in patients with systemic lupus erythematosus. Arthritis Rheum 38:1713–1714

    Article  CAS  PubMed  Google Scholar 

  79. Sullivan KE, Wooten C, Goldman D, Petri M (1996) Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 39:2046–2051

    Article  CAS  PubMed  Google Scholar 

  80. Iliopoulos AG, Tsokos GC (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25:318–336

    Article  CAS  PubMed  Google Scholar 

  81. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW (1999) The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med 190:585–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Salmon JE, Pricop L (2001) Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum 44:739–750

    Article  CAS  PubMed  Google Scholar 

  83. Karassa FB, Trikalinos TA, Ioannidis JP (2002) Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 46:1563–1571

    Article  CAS  PubMed  Google Scholar 

  84. Karassa FB, Trikalinos TA, Ioannidis JP (2003) The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 63:1475–1482

    Article  CAS  PubMed  Google Scholar 

  85. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13:137–147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, Kuroda Y (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313–314

    Article  CAS  PubMed  Google Scholar 

  87. Kyttaris VC, Juang YT, Tsokos GC (2005) Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 17:518–522

    Article  CAS  PubMed  Google Scholar 

  88. Wilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte LB, Emery P, Duff GW (1994) A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 24:191–195

    Article  CAS  PubMed  Google Scholar 

  89. D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P (2000) Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 43:120–128

    Article  PubMed  Google Scholar 

  90. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, Niho Y (2001) Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 44:2819–2827

    Article  CAS  PubMed  Google Scholar 

  91. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52:1491–1503

    Article  CAS  PubMed  Google Scholar 

  92. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PIW, Le JM, Lee H-S, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martin J, Altshuler D, Behrens TW, Alarcon-Riquelme ME (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550–555

    Article  CAS  PubMed  Google Scholar 

  94. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434:243–249

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Institute of Arthritis, Musculoskeletal and skin diseases grant No 1K23 AR055672-01A1

Author information

Authors and Affiliations

  1. Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Vasileios C. Kyttaris

Authors
  1. Vasileios C. Kyttaris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vasileios C. Kyttaris .

Editor information

Editors and Affiliations

  1. PharmTao, Santa Clara, California, USA

    Qing Yan

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Kyttaris, V.C. (2010). Systemic Lupus Erythematosus: From Genes to Organ Damage. In: Yan, Q. (eds) Systems Biology in Drug Discovery and Development. Methods in Molecular Biology, vol 662. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-800-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-800-3_13

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-799-0

  • Online ISBN: 978-1-60761-800-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation